文献速递类风湿关节炎

Sarilumab 改善 TNF 抑制剂应答不足类风湿关节炎患者报告结局

Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
PubMed 文献 · RMD Open · 2017-03-07

TARGET 试验纳入 546 例对肿瘤坏死因子抑制剂应答不足或不耐受的类风湿关节炎患者,随机接受安慰剂或 sarilumab 150/200 mg 每 2 周皮下注射联合 csDMARDs。12 周时 sarilumab 在患者整体评估、疼痛、HAQ-DI、SF-36 与 FACIT-F 等方面较安慰剂改善并维持至 24 周,达到 MCID 及规范值的患者比例更高。

要点

  • sarilumab 两剂量联合 csDMARDs 在 12 周改善多项 PROs 并维持至 24 周。
  • 晨僵、工作与生活参与(WPS-RA、RAID)亦见改善。
  • 达到 MCID 与规范值评分的患者比例高于安慰剂。

核心结论

  • 在 TNF-IR 类风湿关节炎患者中,sarilumab 150 与 200 mg 联合 csDMARDs 在 12 与 24 周产生有临床意义的患者报告获益,优于安慰剂联合 csDMARDs。

研究设计与样本

  • TARGET 试验:546 例 TNF-IR 类风湿关节炎患者(81.9% 女性,平均年龄 52.9 岁)随机接受安慰剂、sarilumab 150 或 200 mg 每 2 周皮下注射联合 csDMARDs。
  • 采用重复测量混合模型分析第 12 与 24 周相对基线的变化,并做事后分析。

主要发现

  • 第 12 周 sarilumab 联合 csDMARDs 在 PtGA、疼痛、HAQ-DI、SF-36 与 FACIT-F 较安慰剂联合 csDMARDs 改善,并维持至第 24 周。
  • sarilumab 改善晨僵,并降低 RA 对工作、家庭、社交/休闲活动参与(WPS-RA)及患者生活(RAID)的影响。
  • 达到改善≥MCID 及≥规范值评分的患者比例,sarilumab 高于安慰剂。

临床怎么用

  • 对 TNF 抑制剂应答不足或不耐受的 RA 患者,sarilumab 联合 csDMARDs 可在疼痛、疲劳、功能与参与方面带来患者报告的有临床意义获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate response or intolerance to tumour necrosis factor inhibitors (TNF-IR). METHODS: 546 patients (81.9% female, mean age 52.9 years) were randomised to placebo, sarilumab 150 or 200 mg subcutaneously every 2 weeks + csDMARDs. PROs included patient global assessment (PtGA); pain and morning stiffness visual analogue scales; Health Assessment Questionnaire Disability Index (HAQ-DI); Short Form-36 Health Survey (SF-36); FACIT-Fatigue (FACIT-F); Work Productivity Survey-Rheumatoid Arthritis (WPS-RA) and Rheumatoid Arthritis Impact of Disease (RAID). Changes from baseline at weeks 12 and 24 were analysed using a mixed model for repeated measures; post hoc analyses included percentages of patients reporting improvements ≥ minimum clinically important differences (MCID) and scores ≥ normative values. RESULTS: Sarilumab + csDMARDs doses resulted in improvements from baseline at week 12 vs placebo + csDMARDs in PtGA, pain, HAQ-DI, SF-36 and FACIT-F that were maintained at week 24. Sarilumab improved morning stiffness and reduced the impact of RA on work, family, social/leisure activities participation (WPS-RA) and on patients' lives (RAID). Percentages of patients reporting improvements ≥MCID and ≥ normative scores were greater with sarilumab than placebo. CONCLUSIONS: In patients with TNF-IR RA, 150 and 200 mg sarilumab + csDMARDs resulted in clinically meaningful patient-reported benefits on pain, fatigue, function, participation and health status at 12 and 24 weeks that exceeded placebo + csDMARDs, and were consistent with the clinical profile previously reported. TRIAL REGISTRATION NUMBER: NCT01709578; Results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Strand V, Reaney M, Chen CI, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open. 2017. PMID: 28326189. doi:10.1136/rmdopen-2016-000416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。